CAR T-cell therapy delivered to the brain shows clinical activity in glioblastoma in phase I study

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

A pioneering phase I CAR T-cell therapy trial for the treatment of glioblastoma at City of Hope, demonstrates promising clinical activity against incurable brain tumors, according to research published in Nature Medicine.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents


More than half of deaths that are not attributed to disease progression or recurrence after CAR T-cell therapy are caused by infections—an unprecedented finding that experts say marks a shift from a conventional focus on mitigating treatment-specific adverse events to including prevention and management of infections.
City of Hope and Charles R. Drew University of Medicine and Science, the only Historically Black Graduate Institution west of the Mississippi River and one of only four Historically Black Medical Schools, announced the launch of a new partnership to educate a more diverse workforce in specialized medicine through internships, curriculum, training, mentorships, joint research projects, and more.